The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
Abstract
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There are genetically determined differences in the activity of this enzyme. The genotypes of CYP2C19 are classified into the three groups, rapid extensive metabolizer (RM), intermediate metabolizer (IM), and poor metabolizer (PM). The pharmacokinetics and pharmacodynamics of PPIs depend on CYP2C19 genotype status. Plasma PPI levels and intragastric pHs during PPI treatment in the RM group are lowest, those in the IM group come next, and those in the PM group are highest of the three groups. These CYP2C19 genotype-dependent differences in pharmacokinetics and pharmacodynamics of PPIs influence the cure rates for the gastro-esophageal reflux disease and H. pylori infection by PPI-based therapies. For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Kuipers, E. J., Lundell, L., Klinkenberg-Knol, E. C., Havu, N., Festen, H. P. M., Liedman, B., Lamers, C. B. H. W., Jansen, J. B. M. J., Dalenbäck, J., Snel, P., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341603 · Cited by 769
De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K., & Goldstein, J. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09788-3 · Cited by 752
Lind, T., van Zanten, S. V., Unge, P., Spiller, R., Bayerdörffer, E., O'Morain, C., Bardhan, K. D., Bradette, M., Chiba, N., Wrangstadh, M., et al. (1996) · Helicobacter · doi:10.1111/j.1523-5378.1996.tb00027.x · Cited by 573
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
Lind, T., Mégraud, F., Unge, P., Bayerdörffer, E., O'Morain, C., Spiller, R., van Zanten, S. V., Bardhan, K. D., Hellblom, M., Wrangstadh, M., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70119-8 · Cited by 434
Ishizaki, & Horai (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00022.x · Cited by 428
The Treatment of Helicobacter pylori Infection in the Management of Peptic Ulcer Disease
Walsh, J. H., & Peterson, W. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331508 · Cited by 383
Gastric precancerous process in a high risk population: cohort follow-up.
Correa, P., Haenszel, W. M., Cuello, C., Zavala, D., Fontham, E., Zarama, G., Tannenbaum, S. R., Collazos, T., & Ruiz, B. (1990) · PubMed · Cited by 375
The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPase
Sachs, G., Shin, J. M., Briving, C., Wallmark, B., & Hersey, S. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.001425 · Cited by 367
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 362
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Alv�n, G., Bechtel, P., Iselius, L., & Gundert-Remy, U. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316090 · Cited by 361
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 335
Self-citationNocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors
Peghini, P. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00101-4 · Cited by 317
Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population*
Kubota, T., Chiba, K., & Ishizaki, T. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90214-3 · Cited by 288
Self-citationThe role of internal urease in acid resistance of Helicobacter pylori
Scott, D. R., Weeks, D., Hong, C., Postius, S., Melchers, K., & Sachs, G. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70633-x · Cited by 284
genotype status and effect of omeprazole on intragastric pH in humans
FURUTA, T., OHASHI, K., KOSUGE, K., ZHAO, X., TAKASHIMA, M., KIMURA, M., NISHIMOTO, M., HANAI, H., KANEKO, E., & ISHIZAKI, T. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70075-5 · Cited by 272
Self-citationFuruta, T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113959 · Cited by 254
Self-citationThe life and death of helicobacter pylori
Scott, D., Weeks, D., Melchers, K., & Sachs, G. (1998) · Gut · doi:10.1136/gut.43.2008.s56 · Cited by 222
Shirai, N., Furuta, T., Moriyama, Y., Okochi, H., Kobayashi, K., Takashima, M., Xiao, F., Kosuge, K., Nakagawa, K., Hanai, H., et al. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01108.x · Cited by 221
Self-citationGoddard, A., Jessa, M., Barrett, D., Shaw, P., Idstrom, J., Cederberg, C., & Spiller, R. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8690200 · Cited by 218
Peterson, W. L., Graham, D. Y., Marshall, B. J., et al. (1993) · PubMed · Cited by 216
Bayerdörffer, E., Miehlke, S., Mannes, G. A., Sommer, A., Höchter, W., Weingart, J., Heldwein, W., Klann, H., Simon, T., Schmitt, W., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90689-4 · Cited by 211
Adamek, R. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(97)00110-x · Cited by 202
Ferguson, R. J., De Morais, S. M. F., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G. R., Sarich, T. C., Wright, J. M., Dayer, P., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37213-1 · Cited by 199
Versalovic, J. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.2.283 · Cited by 195
Gastric precancerous process in a high risk population: cross-sectional studies.
Correa, P., Haenszel, W. M., Cuello, C., et al. (1990) · PubMed · Cited by 185
Chang, M., Tybring, G., Dahl, M., Gotharson, E., Sagar, M., Seensalu, R., & Bertilsson, L. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04488.x · Cited by 184
genotype–related efficacy of omeprazole for the treatment of infection caused by
TANIGAWARA, Y., AOYAMA, N., KITA, T., SHIRAKAWA, K., KOMADA, F., KASUGA, M., & OKUMURA, K. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70017-2 · Cited by 182
Xie, H.-G., Stein, C. M., Kim, R. B., Wilkinson, G. R., Flockhart, D. A., & Wood, A. J. J. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00001 · Cited by 181
Xiao, Z.-S., Goldstein, J. A., Xie, H.-G., Blaisdell, J., Wang, W., Jiang, C.-H., Yan, F.-X., He, N., Huang, S.-L., Xu, Z.-H., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36606-6 · Cited by 174
Andersson, T., Reg??rdh, C.-G., Lou, Y.-C., Zhang, Y., Dahl, M.-L., & Bertilsson, L. (1992) · Pharmacogenetics · doi:10.1097/00008571-199202000-00005 · Cited by 173
Williams, Sercombe, Hamilton, & Pounder (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00418.x · Cited by 168
Slow Omeprazole Metabolizers Are Also Poor S-Mephenytoin Hydroxylators
Andersson, T., Regårdh, C.-G., Dahl-Puustinen, M.-L., & Bertilsson, L. (1990) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199007000-00020 · Cited by 166
Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agents
Grayson, M. L., Eliopoulos, G. M., Ferraro, M. J., & Moellering, R. C. (1989) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/bf01963775 · Cited by 166
Asaka, M., Sugiyama, T., Kato, M., Satoh, K., Kuwayama, H., Fukuda, Y., Fujioka, T., Takemoto, T., Kimura, K., Shimoyama, T., et al. (2001) · Helicobacter · doi:10.1046/j.1523-5378.2001.00037.x · Cited by 158
Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127637 · Cited by 153
Self-citationIdentification of the human P450 enzymes involved in lansoprazole metabolism.
Pearce, R. E., Rodrigues, A. D., Goldstein, J. A., et al. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12938-8 · Cited by 148
Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.
Andersson, T., Miners, J. O., Veronese, M., & Birkett, D. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04310.x · Cited by 146
CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
Adachi, K., Katsube, T., Kawamura, A., et al. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00840.x · Cited by 144
Sohn, D., Kobayashi, K., Chiba, K., Lee, K., Shin, S. G., & Ishizaki, T. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10918-x · Cited by 140
Self-citationResults of a multicentre European survey in 1991 of metronidazole resistance inHelicobacter pylori
European Study Group on Antibiotic Susceptibility of Helicobacter pylori (1992) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01960875 · Cited by 138
Furuta, T., Shirai, N., Takashima, M., Fang, X., Hanai, H., Nakagawa, K., Sugimura, H., Ohashi, K., & Ishizaki, T. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00009 · Cited by 134
Self-citationGenetic analysis of the S-mephenytoin polymorphism in a chinese population*
de Morais, S. M. F., Goldstein, J. A., Xie, H., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90053-5 · Cited by 134
Yamazaki, H., Inoue, K., Shaw, P. M., Checovich, W. J., Guengerich, F. P., & Shimada, T. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37072-7 · Cited by 133
Kuipers, E. J., Lee, A., Klinkenberg–Knol, E. C., et al. (1995) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1995.tb00391.x · Cited by 132
Leite, L. P., Johnston, B. T., Just, R., et al. (1996) · PubMed · Cited by 131
Rapid eradication of Helicobacter pylori infection
Bell, G. D., POWELL, K., BURRIDGE, S. M., BOWDEN, A. F., Atoyebi, W., BOLTON, G., Jones, P. H., & Brown, C. (1995) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1995.tb00349.x · Cited by 129
Ad, R., Roberts, E. M., Dj, M., et al. (1997) · PubMed · Cited by 123
Furuta, T., Ohashi, K., Kobayashi, K., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70034-2 · Cited by 121
Self-citationCYP2C19 genotype and phenotype determined by omeprazole in a Korean population
Roh, H., Dahl, M., Tybring, G., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199612000-00008 · Cited by 118
Miehlke, S., Kirsch, C., Schneider‐Brachert, W., Haferland, C., Neumeyer, M., Bästlein, E., Papke, J. H., Jacobs, E., Vieth, M. W., Stolte, M., et al. (2003) · Helicobacter · doi:10.1046/j.1523-5378.2003.00158.x · Cited by 115
Ishizaki, T., Sohn, D., Kobayashi, K., et al. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199404000-00018 · Cited by 103
Self-citationThe effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
Kawamura, M., Ohara, S., Koike, T., Iijima, K., Suzuki, J., Kayaba, S., Noguchi, K., Hamada, S., Noguchi, M., & Shimosegawa, T. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01539.x · Cited by 102
Langtry, H. D., & Wilde, M. I. (1997) · Drugs · doi:10.2165/00003495-199754030-00010 · Cited by 95
Masimirembwa, C. M., Bertilsson, L., Johansson, I., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90228-7 · Cited by 88
Klinkenberg–Knol, E. C., & Meuwissen, S. G. M. (1990) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1990.tb00495.x · Cited by 83
Review ofHelicobacter pyloriEradication Regimens
Unge, P. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609094541 · Cited by 80
Dojo, M., Azuma, T., Saito, T., Ohtani, M., Muramatsu, A., & Kuriyama, M. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80043-8 · Cited by 79
Cancer After Exposure to Metronidazole
Beard, C. M., Noller, K. L., O’Fallon, W. M., et al. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)64947-7 · Cited by 75
Chronic gastritis as a cancer precursor.
Corréa, P. (1984) · PubMed · Cited by 72
Carswell, C., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161150-00016 · Cited by 71
Genetic polymorphism of (S)‐mephenytoin 4′‐hydroxylation in populations of African descent
Xie, Kim, Stein, Wilkinson, & Wood (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00009.x · Cited by 60
Omeprazole: Its Influence on Gastric Acid Secretion, Gastrin and ECL Cells
Larsson, H., Håkanson, R., Mattsson, H., Ryberg, B., Sundler, F., & Carlsson, E. I. (1988) · Toxicologic Pathology · doi:10.1177/019262338801600220 · Cited by 59
Ushiama, H., Echizen, H., Nachi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.125559 · Cited by 55
Aoyama, N., Tanigawara, Y., Kita, T., et al. (1999) · PubMed · Cited by 53
Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype*
Marinac, J. S., Balian, J. D., Foxworth, J. W., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90129-0 · Cited by 51
Effects of clarithromycin on lansoprazole pharmacokinetics betweenCYP2C19genotypes
Saito, M., Yasui‐Furukori, N., Uno, T., et al. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02329.x · Cited by 47
Inatomi, N., Nagaya, H., Takami, K., Shino, A., & Satoh, H. (1991) · The Japanese Journal of Pharmacology · doi:10.1016/s0021-5198(19)39914-7 · Cited by 44
Singh, P. K. (2000) · World Journal of Gastroenterology · doi:10.3748/wjg.v6.i6.789 · Cited by 43
Cobalamin deficiency with megaloblastic anaemia in one patient under long‐term omeprazole therapy
Bellou, A., Aimone‐Gastin, I., de Korwin, J.-D., Bronowicki, J., Moneret-Vautrin, A., Nicolas, J. P., Bigard, M., & Guéant, J. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.20846000.x · Cited by 43
Lansoprazole and omeprazole in the treatment of acid peptic disorders
Blum, R. A. (1996) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/53.12.1401 · Cited by 40
SAGAR, JANCZEWSKA, Ljungdahl, �., Bertilsson, & SEENSALU (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00490.x · Cited by 38
Sagar, M., Bertilsson, L., Stridsberg, M., Kjellin, A., Mårdh, S., & Seensalu, R. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00835.x · Cited by 38
Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth
Sanduleanu, S., Jonkers, D. M. A. E., A, A. P. D. B., Hameeteman, W. M., & Stockbrügger, R. W. (2001) · Digestive and Liver Disease · doi:10.1016/s1590-8658(01)80050-5 · Cited by 36
Clinical review of lansoprazole.
Lockhart, S. P. (1994) · PubMed · Cited by 6
Cited by
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shi, S., & Klotz, U. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0538-y · Cited by 314
Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH
Kirchheiner, J., Glatt, S., Fuhr, U., Klotz, U., Meineke, I., Seufferlein, T., & Brockmöller, J. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0576-5 · Cited by 277
Acid Suppression Therapy: Where Do We Go from Here?
Scarpignato, C., Pelosini, I., & Di Mario, F. (2006) · Digestive Diseases · doi:10.1159/000091298 · Cited by 119
Pachkoria, K., Lucena, M. I., Ruiz‐Cabello, F., Crespo, E., Cabello, M. R., Andrade, R. J., & on behalf of the Spanish Group for the Study of Drug‐Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM) (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707122 · Cited by 49
Tulain, U. R., Ahmad, M., & Rashid, A. (2018) · Polymer-Plastics Technology and Engineering · doi:10.1080/03602559.2018.1434668 · Cited by 16
Metadata
- Authors
- Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A., & Ishizaki, T.
- Venue
- Drug Metabolism and Pharmacokinetics
- Published
- 2005
- Volume
- 20
- Issue
- 3
- Pages
- 153-167
- ISSN
- 1347-4367 (ISSN-L)
- OpenAlex
- W2056770708
- Cited by
- 257
- References
- 76
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.